Esophagogastric Variceal Bleeding
Conditions
Interventions
experimental group:probiotics+routine treatment
control group:Placebo
Sponsors
Beijing Ditan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
15 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18–75 years old; 2. Esophagogastric variceal bleeding in Liver Cirrhosis Patients 3. Informed and signed informed consent
Exclusion criteria
Exclusion criteria: 1. liver or other organ malignancies before or during the first admission period; 2. Have suffered from severe cardiovascular system, digestive system, respiratory system, urinary system and other organ dysfunction or insufficiency during past or enrollment; 3. Patients have previous bleeding history and other diseases that can cause bleeding (ulcerative diseases, gastric mucosal lesion, idiopathic thrombocytopenic purpura, or other hematological disease); 4. Combined with systemic infection at the time of enrollment; 5. Patients undergoing liver transplantation, splenectomy, TIPSS, surgical disconnection and shunt before enrollment; 6. Those who used of probiotics, antibiotics, antifungal drugs, hormones, etc. that affect the micro-ecological status within one month; 7. severe neurological or psychiatric disorders; 8. alcohol abuse and/or other drug overuse; 9. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of rebleeding;16SrDNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| liver function;complication;untoward reaction;mortality; | — |
Countries
China
Contacts
Public ContactWang Xianbo
Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University
Outcome results
None listed